Keywords
Abstract
Hypothyroidism is a known side effect of treatment of MDR-tuberculosis. Only a few studies describe this syndrome due to thioureidoimiminopyridinium perchlorate. A retrospective study of 14 tuberculosis patients receiving thioureidoimiminomethylpyridinium perchlorate was performed. As a comparison group, 10 patients with hypothyroidism were selected, but without tuberculosis. Despite a significant increase in the level of thyroid-stimulating hormone (TSH) in patients with tuberculosis (up to 185 mIU/L, an average of 59.1 versus 8.7 in the comparison group), only complaints of facial swelling, decreased appetite and irritability were detected more often reliably in the main group. Increased concentrations of TSH were detected on average 86 days after the start of therapy. Of laboratory parameters that change with thyroid hormone deficiency, only hemoglobin concentration was significantly lower in patients with tuberculosis. Hypothyroidism in patients with tuberculosis was corrected by large doses of levothyroxine (96.4 vs. 72.5 ?g), but with respect to the level of TSH - lower than in the comparison group. The elimination of thioureidiminomethylpyridinium perchlorate was not required. The thyroid status should be monitored monthly during the treatment with thioureidoiminomethylpyridinium perchlorate.